Research on the multi-dimensional value assessment framework for new antidiabetic drugs to support evidence-informed medical insurance decision-making

YAN Feifei; CHEN Jingyu; CHEN Jiaran; PAN Chen; WANG Guohua; GENG Jinsong

doi:10.6039/j.issn.1001-0408.2025.13.02

您当前的位置：

首页 >

文章列表页 >

Research on the multi-dimensional value assessment framework for new antidiabetic drugs to support evidence-informed medical insurance decision-making

更新时间：2025-09-24

- Research on the multi-dimensional value assessment framework for new antidiabetic drugs to support evidence-informed medical insurance decision-making
- ZHONGGUO YAOFANG Vol. 36, Issue 13, Pages: 1563-1567(2025)
- 作者机构：
  
  1.南通大学医学院医学信息学系，江苏南通　226001
  2.首都医科大学宣武医院/国家老年疾病临床医学研究中心，北京　100053
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.13.02
  CLC： R977.1+5
- Received：11 December 2024，
  
  Revised：2025-04-16，
  
  Accepted：17 April 2025，
  
  Published：15 July 2025
- 稿件说明：
移动端阅览
颜菲菲,陈靖宇,陈家然,等.支持医保知证决策的降糖新药多维价值评估框架研究[J].中国药房,2025,36(13):1563-1567.

YAN Feifei,CHEN Jingyu,CHEN Jiaran,et al.Research on the multi-dimensional value assessment framework for new antidiabetic drugs to support evidence-informed medical insurance decision-making[J].ZHONGGUO YAOFANG,2025,36(13):1563-1567.
颜菲菲,陈靖宇,陈家然,等.支持医保知证决策的降糖新药多维价值评估框架研究[J].中国药房,2025,36(13):1563-1567. DOI： 10.6039/j.issn.1001-0408.2025.13.02.

YAN Feifei,CHEN Jingyu,CHEN Jiaran,et al.Research on the multi-dimensional value assessment framework for new antidiabetic drugs to support evidence-informed medical insurance decision-making[J].ZHONGGUO YAOFANG,2025,36(13):1563-1567. DOI： 10.6039/j.issn.1001-0408.2025.13.02.

摘要

目的

基于多准则决策分析理论构建降糖新药的多维价值评估框架，为医保知证决策提供理论框架和方法学借鉴。

方法

首先，通过系统检索和获取多维度证据，为框架建立提供数据支持。其次，基于获取的证据，采用内部专题小组讨论的方式，初步构建价值评估框架，确定框架的结构、核心准则以及情境化准则。最后，通过专家咨询进一步确定框架的准则和子准则及其权重，明确子准则的纳入依据和参考评分的合理性并优化评估方法。

结果

降糖新药多维价值评估框架由核心准则和情境化准则组成，分别用于新药价值的量化评估和定性评价。核心准则由5个维度组成，重要性由高到低依次是可负担性（6.31）、相对有效性（6.20）、相对安全性（6.01）、经济性（5.89）和证据质量（5.46）；子准则权重被归一化校正后，医保预算影响成为了具有最高标化权重的子准则，其次是糖化血红蛋白的控制和患者的可负担性。情境化准则包括2个维度，即创新性和公平性。

结论

所建评估框架整合了证据、利益相关方的价值诉求和决策情境，有助于实现降糖新药价值的多维度和循证评估。

Abstract

OBJECTIVE

To establish a multi-dimensional value assessment framework for new antidiabetic drugs based on multi-criteria decision analysis theory， thus providing a theoretical framework and methodology for evidence-informed medical insurance decision-making.

METHODS

Firstly， multi-dimensional evidence was searched and obtained to provide reliable data for the establishment of the framework. Secondly， in terms of the obtained evidence， the value assessment framework was preliminarily constructed. Its structure， main core criteria， and contextual criteria were determined through focus group discussion. Finally， the criteria and sub-criteria of the framework and their weights were further determined， reasons for inclusion of sub-criteria and the reasonableness of rating scores were evaluated， and methods of assessment were optimized through expert consultation.

RESULTS

The multi-dimensional value assessment framework for new antidiabetic drugs was composed of core criteria and contextualized criteria， which could be used for quantitative and qualitative value assessment of new drugs， respectively. The core criteria consisted of five dimensions， with affordability （6.31） having the highest weighting score， followed by comparative effectiveness （6.20）， comparative safety （6.01）， cost-effectiveness （5.89）， and quality of evidence （5.46）. After the normalization of weight within sub-criteria， the budget impact on medical insurance had the highest standardized weight， followed by the control of glycated hemoglobin and patient affordability. The contextual criteria included two dimensions， i.e.， innovation and equity.

CONCLUSIONS

The assessment framework integrates evidence， stakeholders’ values， and decision contexts to enable a multi-dimensional and evidence-based assessment of the value of new antidiabetic drugs.

关键词

Keywords

references

LIU J L ， LIU M ， CHAI Z L ， et al . Projected rapid growth in diabetes disease burden and economic burden in China：a spatio-temporal study from 2020 to 2030 [J ] . Lancet Reg Health West Pac ， 2023 ， 33 ： 100700 .

CHEN Y Y ， DONG H J ， WEI Y ， et al . Using health technology assessment to inform insurance reimbursement of high technology medicines in China：an example of cancer immunotherapy [J ] . BMJ ， 2023 ， 381 ： e069963 .

CHEN W ， ZHANG L Y ， HU M ， et al . Use of health technology assessment in drug reimbursement decisions in China [J ] . BMJ ， 2023 ， 381 ： e068915 .

World Health Organization . Evidence，policy，impact：WHO guide for evidence-informed decision-making [R ] . Geneva ： World Health Organization ， 2021 .

BAO Y ， GAO B ， MENG M ， et al . Impact on decision making framework for medicine purchasing in Chinese public hospital decision-making：determining the value of five dipeptidyl peptidase 4 （DPP-4） inhibitors [J ] . BMC Health Serv Res ， 2021 ， 21 （ 1 ）： 807 .

耿劲松，陈晓炜，余小兰，等 . 基于EVIDEM的新技术医保报销循证决策框架探析 [J ] . 中国卫生政策研究， 2018 ， 11 （ 4 ）： 50 - 54 .

胡善联 . 多准则决策分析在卫生决策领域中的应用价值 [J ] . 中国卫生资源， 2020 ， 23 （ 4 ）： 325 .

戴泽琦，景城阳，吴雪，等 . 基于EVIDEM框架的中成药临床综合评价指标体系构建及解读 [J ] . 中国实验方剂学杂志， 2024 ， 30 （ 6 ）： 134 - 143 .

刘国恩 . 中国药物经济学评价指南2020 [M ] . 北京：中国市场出版社， 2020 ： 27 - 76 .

陈耀龙，杨克虎，王小钦，等 . 中国制订/修订临床诊疗指南的指导原则： 2022版 [J ] . 中华医学杂志， 2022 ， 102 （ 10 ）： 697 - 703 .

SHEA B J ， REEVES B C ， WELLS G ， et al . AMSTAR 2：a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions，or both [J ] . BMJ ， 2017 ， 358 ： j4008 .

FLEMYNG E ， MOORE T H ， BOUTRON I ， et al . Using risk of bias 2 to assess results from randomised controlled trials：guidance from Cochrane [J ] . BMJ Evid Based Med ， 2023 ， 28 （ 4 ）： 260 - 266 .

HUSEREAU D ， DRUMMOND M ， AUGUSTOVSKI F ， et al . Consolidated health economic evaluation reporting standards 2022 （CHEERS 2022） statement：updated reporting guidance for health economic evaluations [J ] . Value Health ， 2022 ， 25 （ 1 ）： 3 - 9 .

GASOL M ， PACO N ， GUARGA L ， et al . Early access to medicines：use of multicriteria decision analysis （MCDA） as a decision tool in Catalonia （Spain） [J ] . J Clin Med ， 2022 ， 11 （ 5 ）： 1353 .

潘慧敏，王钰博，陈迹，等 . 达格列净治疗2型糖尿病合并心血管疾病的快速卫生技术评估 [J ] . 中国药房， 2024 ， 35 （ 18 ）： 2293 - 2298 .

黄文娟，崔梦茹，阿卜杜如苏力·吾舒尔，等 . 胰高血糖素样肽1受体激动剂周制剂的Mini卫生技术评估 [J ] . 中国药房， 2023 ， 34 （ 14 ）： 1768 - 1773 .

鲍海妮，余小兰，耿劲松，等 . 医药卫生领域多准则决策分析的方法学 [J ] . 中国卫生资源， 2020 ， 23 （ 4 ）： 337 - 341，372 .

LABA T L ， JIWANI B ， CROSSLAND R ， et al . Can multi-criteria decision analysis （MCDA） be implemented into real-world drug decision-making processes：a Canadian provincial experience [J ] . Int J Technol Assess Health Care ， 2020 ： 1 - 6 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

⁰